Dialysis Tubing Research Articles

Dexamethasone-loaded fibroin nanoparticles promote retinal reattachment in rats by regulating the Th17/Treg balance.

Purpose
Retinal detachment (RD) is a common acute blinding eye disease. DEX, an adrenocorticosteroid drug, has predominant protective effects on RD. However, given its poor water solubility and low bioavailability, we aimed to develop an alternative nano-based treatment approach to investigate the effects and underlying mechanisms of RD.
Methods
SF@DEX nanomaterials were synthesized and then successfully characterized. In vitro, phagocytosis was measured by flow cytometry. The expression levels of IL-17 and IL-10 were determined by ELISA. A rat model of RD was established by surgery. Then, rats were orally administered with SF, SF@DEX, and DEX, respectively. The level of IL-17A and FOXP3 was assessed by PCR, and the expression levels of TGF-β1, IL-10, IL-17A, and FOXP3 were detected by Western blot. The apoptotic level of retinal ganglion cells (RGCs) in retinal tissue was measured by TUNEL assay, and confocal microscopy was used to detect changes in the colocalization content of IL-17A and FOXP3 in retinal tissue.
Results
Our results demonstrated that the nanoparticles exhibited good stability. The encapsulation efficiency (EE) was 90%, and approximately 60% of DEX was released within 12 hours from the dialysis bag. In vivo, after treatment with SF@DEX, the expression of Th17 cells and IL-17A significantly decreased, while the expression levels of Tregs, FOXP3, TGF-β1, and IL-10 were increased. Furthermore, SF@DEX nanomaterial treatment markedly alleviated the severity of RD in rats.
Conclusion
Taken together, these findings demonstrate that SF@DEX can protect against RD and inhibit inflammation, mediated by regulating the Th17/Treg immune balance.&#xD.

In vitro and in vivo characterization of Invega Sustenna® (paliperidone palmitate long-acting injectable suspension).

The aim of this study was to comprehensively characterize paliperidone palmitate (PP) long-acting suspension (Invega Sustenna®) through reverse engineering. We developed a series of analytical methods to assess critical quality attributes of four batches of Invega Sustenna®. The size distributions of the four batches of suspensions were measured using laser diffraction, and variations in the D50 and D90 parameters were observed. The morphology of suspension was determined through scanning electron microscope (SEM), which exhibited irregular granular shape across all batches. The size distributions determined by SEM images were similar to the laser diffraction results. Thermal characteristics were detected using differential scanning calorimetry (DSC) and crystalline properties were assessed by powder X-ray diffraction (PXRD), displaying consistency among the four batches in these two aspects. In vitro dissolution methods (sample separation and dialysis bag methods) were developed to evaluate the release behaviors of Invega Sustenna® and four lots showed a similar dissolution pattern. Furthermore, following a single-dose intramuscular administration to rats, two batches of Invega Sustenna® with the largest size differences demonstrated comparable plasma concentration-time profiles and pharmacokinetics parameters, indicative of one month long-acting release. In summary, we established a systematic quality characteristics assessment for Invega Sustenna®, including particle size distribution, particle morphology, thermal characteristics, crystalline properties, in vitro dissolution kinetics and in vivo pharmacokinetics. Our work will assist pharmaceutical companies and regulatory agencies in the development and regulatory assessment of novel or generic products of long-acting injectable suspension.

Improving peritoneal dialysis fluid culture-positivity yield from 2022 to 2023.

Microbiological testing of peritoneal dialysis bags for peritonitis often yields culture-negative results. Culture-negative samples should not exceed > 15% according to the International Society for Peritoneal Dialysis. To reduce this issue, the addition of a blood culture bottle incubation step to the culture process was introduced at the Infection Control Services Laboratory (ICSL) of the National Health Laboratory Services (NHLS). The aim of the study was to ascertain if the change in methodology increased the culture-positivity yield and reduced the culture-negative percentage. Data from the NHLS Central Data Warehouse (CDW) were analysed to compare the culture-positive results over two periods: June-December 2022 when the non-blood culture (B/C) bottle method was used and January-July 2023 when the B/C bottle method was implemented. The non-B/C culture method yielded a 23% culture-positivity yield, whereas the B/C bottle-based method yielded a 51% culture-positivity yield. However, the culture-negative yield for the B/C bottle-based method was high at 49%. The change in dialysis bag processing in 2023 led to a more than doubling in culture-positivity yield. However, the culture-negative percentage remained high. As a result, further modifications to the methodology are needed. The study findings illustrate that the addition of the B/C bottle incubation step significantly improved peritoneal dialysis bag culture yields which directly impacts patient management.

In vitro transdermal release of crocin from electrospun saffron and its comparison with in vitro digestion

Saffron extract (SE) was electrospun into pullulan-pectin (Pl-Pc), pullulan-pea protein-pectin (Pl-Pp-Pc), or zein nanofibers (NFs) for transdermal food supplement. The in vitro transdermal permeation mechanism and kinetics of SE from NFs were studied and compared with those of in vitro digestion. The ATR-FTIR spectra of NFs provided information on the interactions between SE and wall biopolymers. The release of SE from NFs was investigated in stimulated gastrointestinal media (SGF and SIF) using a dialysis bag, and transdermal permeation studies were performed via a membrane in a Franz diffusion cell. The wettability and swelling ratio of the NFs were determined. The Pl-Pc-SE sample, which has the lowest contact angle and the highest swelling index, resulted in the highest release of SE during digestion. The Ritger-Peppas and Higuchi models best represented the experimental release data from digestion and transdermal permeation. The release profile of SE from zein NFs in SGF was described using a non-Fickian mechanism. In contrast, the release mechanism for Pl-based NFs in SGF and all NFs during both release experiments was Fickian-controlled diffusion transport. The results indicate that NFs can be successfully used for the controlled delivery of SE and have the potential for transdermal applications as a dietary supplement.

FORMULATION, CHARACTERIZATION AND OPTIMIZATION OF PLGA-CHITOSAN-LOADED FATTY ACID SCAFFOLDS FOR THE TREATMENT OF DIABETIC WOUNDS

Objective: The objective of the current research to formulate Eicosapentanoic Acid/Decosahexanoic Acid (EPA/DHA)incorporated into Chitosan (CS)and Poly-Lactic-Glycolic Acid (PLGA), nanoparticles composite scaffolds to the accelerated diabetic wound healing. The main focus of this present research is to evaluate and develop the chitosan–PLGA biodegradable polymer scaffolds loaded with long-chain omega-3 Polyunsaturated Fatty Acids (PUFA’s) (EPA/DHA). Methods: Nano scaffolds were prepared by solvent evaporation method loaded with CS-PLGA, EPA and DHA to treat diabetic wounds at targeted site as pharmacotherapeutically. Upon investigation, the developed biodegradable crosslinked scaffold possesses matrix degradation, optimal porosity, prolonged drug release action than the non-cross linked scaffold. The prepared formulation containing CS-PLGA loaded with EPA/DHA were formulated as nanoscaffold for wound topical applications was carried out by using freeze drying process. Results: The prepared CS-PLGA nano scaffolds were optimized and evaluated for physicochemical properties, dynamic light scattering with a particle size of 248 nm and zeta of-24mVand Scanning Electron Microscopy (SEM) were found to be spherical. In addition, the optical properties of EPA/DHA and PLGA, along with CS, can be compared by examining their absorption and wavelength (nm) using UV-visible spectroscopy. The structural and functional groups of the prepared end products were characterized by Fourier-Transformed Infrared Spectroscopy (FT-IR) has shown good compatibility with excipients and nanoformulaton, in vitro drug release studies done by using dialysis bag membrane results find that first-order Higuchi model was followed showing 20% release in first 0.2 h. MTT(3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide) assay was carried out and it showed that both crosslinked and non-crosslinked scaffolds(110 and 120%) improved cell growth when compared to control (100%). Conclusion: Finally, the results showed that the PLGA, CS nanoscaffolds containing 98% of PUFA’s (EPA/DHA) have increased in proinflammatory cytokines production at the particular wound site and thus accelerated healing activity, depending on the pre-clinical studies have trespassed, the therapeutic potential to penetrating at wound site. The optimized nanoformulation could be a better formulation for targeting and treatment of diabetic wounds at an optimal ratio.

Low-Intensity Focused Ultrasound-Responsive Phase-Transitional Liposomes Loaded with STING Agonist Enhances Immune Activation for Breast Cancer Immunotherapy.

Background: Pharmacologically targeting the STING pathway offers a novel approach to cancer immunotherapy. However, small-molecule STING agonists face challenges such as poor tumor accumulation, rapid clearance, and short-lived effects within the tumor microenvironment, thus limiting their therapeutic potential. To address the challenges of poor specificity and inadequate targeting of STING in breast cancer treatment, herein, we report the design and development of a targeted liposomal delivery system modified with the tumor-targeting peptide iRGD (iRGD-STING-PFP@liposomes). With LIFU irradiation, the liposomal system exploits acoustic cavitation, where gas nuclei form and collapse within the hydrophobic region of the liposome lipid bilayer (transient pore formation), which leads to significantly enhanced drug release. Methods: Transmission electron microscopy (TEM) was used to investigate the physicochemical properties of the targeted liposomes. Encapsulation efficiency and in vitro release were assessed using the dialysis bag method, while the effects of iRGD on liposome targeting were evaluated through laser confocal microscopy. The CCK-8 assay was used to investigate the toxicity and cell growth effects of this system on 4T1 breast cancer cells and HUVEC vascular endothelial cells. A subcutaneous breast cancer tumor model was established to evaluate the tumor-killing effects and therapeutic mechanism of the newly developed liposomes. Results: The liposome carrier exhibited a regular morphology, with a particle size of 232.16 ± 19.82 nm, as indicated by dynamic light scattering (DLS), and demonstrated low toxicity to both HUVEC and 4T1 cells. With an encapsulation efficiency of 41.82 ± 5.67%, the carrier exhibited a slow release pattern in vitro after STING loading. Targeting results indicated that iRGD modification enhanced the system's ability to target 4T1 cells. The iRGD-STING-PFP@liposomes group demonstrated significant tumor growth inhibition in the subcutaneous breast cancer mouse model with effective activation of the immune system, resulting in the highest populations of matured dendritic cells (71.2 ± 5.4%), increased presentation of tumor-related antigens, promoted CD8+ T cell infiltration at the tumor site, and enhanced NK cell activity. Conclusions: The iRGD-STING-PFP@liposomes targeted drug delivery system effectively targets breast cancer cells, providing a new strategy for breast cancer immunotherapy. These findings indicate that iRGD-STING-PFP@liposomes could successfully deliver STING agonists to tumor tissue, trigger the innate immune response, and may serve as a potential platform for targeted immunotherapy.

Hyponatremia in Critically Ill Patients Due to Continuous Venovenous Hemofiltration With Diluted Sodium Citrate.

Continuous venovenous hemofiltration (CVVH) is frequently performed in critically ill patients using diluted citrate for regional anticoagulation. The impact of this renal replacement strategy on plasma sodium has not been evaluated yet. Our aim was therefore to assess the period prevalence of hyponatremia (sodium <135 mmol/L) during CVVH and discuss possible underlying mechanisms. After 48 hours of treatment, 70% of the 27 oligo-anuric critically ill patients were hyponatremic, despite the use of dialysis fluid bags (Regiocit 18/0, Phoxilium by Baxter, Deerfield, IL, and Multibic K2 by Fresenius Medical Care AG & Co. KGaA, Bad Homburg, Germany) with sodium content of 140 mmol/L. Indeed, sodium decreased from 142 ± 7 to 135 ± 3 mmol/L, p < 0.001. Sodium concentrations of employed dialysis bags were confirmed using ion chromatography. However, ionized sodium of Regiocit measured with a direct-ion selective electrode (ISE) resulted lower (~118 mmol/L), suggesting the presence of sodium-to-citrate complexes. Possible mechanisms explaining the hyponatremia development could therefore include: i) plasma water dilution; ii) a reduced Gibbs-Donnan effect, given the low albumin concentration (2.6 ± 0.8 g/dl) of our critically ill patients; iii) a negative sodium balance due to the loss of sodium-to-citrate complexes across the filter. The clinical implications of the described hyponatremia and the different contributions of the hypothesized mechanisms need to be addressed in future studies.

Development and optimization of an in vitro release assay for evaluation of liposomal irinotecan formulation

Onivyde®, a pegylated irinotecan liposomal formulation, is approved by the USFDA for treating metastatic pancreatic adenocarcinoma. Despite the substantial interest in developing its generic versions, the unique structural and manufacturing complexities of liposomal formulations pose challenges. In this study, we address this gap by developing a robust in vitro release test (IVRT) using dialysis membrane techniques. The release of Onivyde® is influenced by several key factors, including the composition of the release medium, temperature, initial formulation concentration, the materials and molecular weight cut-offs of dialysis bags, and the pH of the release medium. Our optimized IVRT for Onivyde® incorporates a release medium containing 5 mM ammonium bicarbonate in a HEPES solution with a pH of 7.4. Additionally, the method includes an initial formulation concentration of 4.6 µg/mL and 50 kDa dialysis bags, while maintaining a temperature of 37 °C with continuous agitation at 80 rpm. This optimized IVR assay effectively differentiates between varying qualities of irinotecan liposomal formulations. Our findings contribute to optimizing IVRT for liposomal irinotecan formulations, enabling better quality control procedures. This assay serves as a reliable tool for evaluating generic irinotecan liposomal formulations, aiding in their development and ensuring in vitro comparability.

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA-chitosan nanoparticles.

The basic purpose of this work was to develop environmentally friendly, biodegradable, and biocompatible polymeric nanoparticles of sorafenib that can effectively release the desired drug in a customized and controlled manner for targeting hepatocellular carcinoma. The solvent evaporation technique was employed for the synthesis of sorafenib-loaded PLGA-chitosan nanoparticles, followed by various experimental specifications and compatibility studies using poloxamer 407 as the stabilizer. The best nanoparticles thus synthesized were selected to be used for cytotoxicity investigations through in vitro and in vivo assessments. For the in vitro drug release tests, the dialysis bag diffusion technique was used. For both chitosan nanoparticles and PLGA loaded with sorafenib, a biphasic release pattern was found, exhibiting a protracted release lasting 10 days after a 24-h burst release. As experimental animals, rabbits were utilized to evaluate different in vivo pharmacokinetic properties of the selected formulations. Plasma samples were extracted with acetonitrile and analyzed through the developed HPLC method. Pharmacokinetic parameters such as AUC0-t, Cmax MRT, Vd, and half-life (t1/2) were enhanced significantly (p ≤ 0.001), while clearance was considerably decreased (p ≤ 0.001) for the chosen synthesized nanoparticles in contrast to the commercially accessible sorafenib formulation (Nexavar®). The cytotoxicity of the reference drug and sorafenib-loaded PLGA and chitosan nanoparticles was calculated by performing an MTT assay against HepG2 cell lines. The developed polymeric sorafenib nanoformulations possess the appropriate physicochemical properties, better targeting, surface morphology, and prolonged release kinetics. The pharmacokinetic parameters were improved significantly when the results were compared with commercially available sorafenib formulations.

Оценка степени высвобождения и токсичности соединений цинка, используемых в фармацевтических и косметических средствах

The degree of release from ointments and the toxicity of three zinc compounds were assessed to establish their minimum sufficient concentration in antibacterial pharmaceutical and cosmetic products. The properties of zinc oxide (ZnO), zinc pyrrolidone carboxylate (ZnРСА) and zinc salicylate (Zn(Sal)2·2H2О) were compared. The release rate of active substances from petrolatum-based ointments (the mass fraction of zinc compounds is 1%) was determined by the Kruvchinsky method. A cellophane film for dialysis served as a semipermeable membrane, which was fixed on a glass tube (length 15 cm, cross section 20 mm2). A sample of ointment (2.00 g) was applied to the inner surface of the membrane. The dialysis tube was inserted into a beaker with dialysis medium and immersed to a depth of no more than 3 mm. The toxicity of aqueous solutions (distilled water) of zinc compounds was determined in a bioluminescent biotest using “Ecolume” bacterial preparation based on a non-pathogenic strain of Escherichia coli. It was found that a high level of toxicity of is achieved at 10-5 mol/dm3 zinc salts in a solution, zinc oxide – 10-4 mol/dm3. A similar amount of Zn2+ diffuses from ointments through a semipermeable cellophane membrane used for the study of dialysis into a 50% aqueous alcohol solution. Zinc ion release from ointment with ZnO was only 0.31%, as well as from ointments with ZnPCA and Zn(Sal)2·2H2О – 1.59% and 1.87% respectively. Thus, the tested approach is economically and environmentally effective, as it allows you to determine the lowest effective concentration of active substances, reducing the burden on the human microbiome and the environment.

Graphene-Based Nano Drug Delivery of Curcumin for the Treatment of Dengue Fever.

Graphene, which is defined as a single-layered sp2 hybridized carbon atoms placed in a honeycomb-like crystal lattice when converted to graphene oxide, has proven its worth by showing its tremendous capacity in controlling the release rate of drugs by entrapping in the numerous pockets present inside it through π-π stacking interaction when used as a nanocarrier. In this experiment graphene oxide was synthesized through traditional Hummer’s method and was used as a nanocarrier to target nanosized drugs, which was prepared by loading curcumin drug into the PVP functionalized graphene oxide by using necessary procedures. After the successful confirmation of the stability, functionalization, and compatibility through various characterization procedures and effective drug loading into the systems, the release behavior of the formulations has been checked through dialysis bag diffusion technique using potassium phosphate buffer saline (pH 7.2, 4.0 and 9.2) for selection of the best medium for determination of the successful sustained-release behavior of the drugs through the dialysis membrane which concluded with satisfactory, sustained and constant drug release phenomenon in the acidic environment reflecting an idea of the fact its favorable release in acidic pH. It is a fact known that dengue fever causes systemic acidosis i.e., reduction of the pH of blood below 7. Thus, when used in-vivo there is a possibility that the formulation has easy access to its target and, performs the desired mechanism of action and can be used as a therapeutic delivery system against the Dengue virus.

Preparation, Evaluation and Optimization of Polymeric Nanoparticles of Eluxadoline for the Treatment of Irritable Bowel Syndrome

ABSTRACT Eluxadoline, exhibits potential as an irritable bowel syndrome treatment and management strategy. Eluxadoline, a muopioid receptor agonist and delta-opioid receptor antagonist, has shown efficacy in relieving IBS symptoms. However, its applications have been limited due to low water solubility, which causes a low dissolution rate and oral bioavailability. In this study, we aimed to enhance the therapeutic efficacy of eluxadoline by formulating polymeric nanoparticles of eluxadoline. Polymeric nanoparticles of chitosan loaded with eluxadoline were prepared using the ionic gelation method. The formulation parameters including concentration of chitosan, concentration of tripolyphosphate and volume of tripolyphosphate were systematically optimized using a Box-Behnken design to achieve nanoparticles (CNP1-CNP17) with optimal physicochemical properties. The optimized formulation based on particle size of (300.4 nm) with a low PDI value (0.305), zeta potential (41.2mV) and % entrapment efficacy (76.89%). The efficiency of the drug release from optimised formulation was studied in vitro by using a dialysis bag diffusion technique in buffer condition pH 6.8 intestinal condition and showed a sustained release behaviour with maximum drug release 80.23%. Thus, the findings demonstrated that the formulated chitosan-based polymeric nanoparticles present a promising strategy for efficiently delivering eluxadoline via oral administration, offering a potential solution for treating irritable bowel syndrome.

Formulation and Evaluation of Nano-particles Loaded with Salvia miltiorriza by Homogenization Method

Aims: The aim of the present study is to formulate and evaluate the Salvia miltorrhizaloaded Nano-structured lipid carriers(SM-NLC) in order to enhance the aqueous solubility and bioavailability as the efficacy of Salvia miltiorriza extract has been restricted due to less solubility and low bioavailability. Introduction: Salvia miltiorrhiza is a well-known Chinese herb that belongs to the family Labiatae. The herb has been widely used to treat various kinds of ailments, and its main phytochemical constituents are Tanshinone I, Tanshinone II, Miltirone, and Salvionolic acid, which are mainly found in the extract of roots. These Phytochemical constituents are responsible for several pharmacological activities such as anti-oxidant, anti-microbial, anti-hyperlipidemic, anti-inflammatory, cardiovascular diseases etc. Objective: Nano-lipid carriers are useful in enhancing the solubility of poor water-soluble drugs. The faulty lattice arrangement of Nano-lipid carriers (NLC) provides better entrapment, thus providing more space for the drug to incorporate in the lattice structure of NLC, improving the stability of the formulation and preventing the drug leakage from the matrix. Methods: SM-NLCs were prepared by using oleic acid and stearic acid as liquid and solid lipids, respectively and tween 80 as the surfactant by high-speed homogenization method. The optimization of SM- NLC was performed by applying the Box-Behnken experimental design. The independent variables were chosen as the amount of lipids, surfactant concentration, and sonication time, whereas dependent variables were opted as particle size and entrapment efficiency. The influence of different proportions of the lipids (Stearic acid and Oleic acid) and the surfactant (Tween 80) was analysed on the dependent variables. The optimized formulation was evaluated for Particle size (241.7nm±3), Polydispersity index (.249 ±0.05), Zeta Potential (-14.6±5), and entrapment efficiency (82.49%). Scanning Electron Microscopy (SEM) was performed to identify the surface morphology, and the entrapment of the drug into the nanostructured matrix was verified by Differential Scanning Calorimetry. The interaction between the formulations was confirmed by performing FTIR. The dialysis bag method was performed to calculate the in vitro drug release from the optimized formulation. Additionally, a stability study was performed for 1 month of duration. Result: The SM NLCs were successfully formulated based on the Box-Behnken design. Particle size, PDI, zeta potential, and EE demonstrated less than a 5% difference compared to the predicted value. The formulations did not show any possible interactions with the lipids. The optimized formulations were found stable after one month of stability studies. Conclusion: The above results confirmed that Salvia miltiorrhiza could be effectively formulated in the form of a nanostructured-lipid carrier system. The formulation and evaluation of nanoparticles have been performed successfully using the homogenization method.

Ultrasound-Induced Release Profile of Nimodipine from Drug-Loaded Block Copolymers after Singular vs. Repeated Sonication: In Vitro Analysis in Artificial Cerebrospinal Fluid.

Nimodipine still represents a unique selling point in the prevention of delayed cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH). Its intrathecal effect is limited by a low oral bioavailability, leading to the development of nanocarrier systems to overcome this limitation. This study investigated the ultrasound-induced release profile of nimodipine from drug-loaded copolymers in artificial cerebrospinal fluid (CSF) within 72 h after a singular versus repeated sonication. Pluronic® F127 copolymers (Sigma-Aldrich, Taufkirchen, Germany)were loaded with nimodipine by direct dissolution. Spontaneous and on-demand drug release by ultrasound (1 MHz at 1.7 W/cm2) was determined in artificial cerebrospinal fluid using the dialysis bag method. Nimodipine concentrations were measured at predefined time points within 72 h of sonication. Spontaneous release of nimodipine was enhanced by ultrasound application with significantly increased nimodipine concentrations two hours after a repeated sonication compared to a singular sonication (median 1.62 vs. 17.48 µg/µL, p = 0.04). A further trend was observed after four hours (median 1.82 vs. 22.09 µg/µL, p = 0.06). There was no difference in the overall nimodipine concentrations between the groups with a singular versus repeated sonication (357.2 vs. 540.3 µg/µL, p = 0.60) after 72 h. Repeated sonication resulted in an acceleration of nimodipine release from the drug-loaded copolymer in a CSF medium. These findings confirm the proof of principle of an on-demand guidance of nimodipine release from nimodipine-loaded nanodrugs by means of ultrasound, which suggests that evaluating the concept in an animal model may be appropriate.

Convolvulus pluricaulis - Lipid hybrid nanoparticles to enhance in vivo exposure and uptake of rivastigmine for alzheimer disease

This study investigates Rivastigmine Hydrogen Tartrate (RHT)-loaded polymeric lipid hybrid nanoparticles (PLHNs) incorporating Shankhpushpi (Convolvulus Pluricaulis; C. Pluricaulis) extract. C. Pluricaulis was extracted using methanol, and PLHNs were formulated using a modified film hydration method with RHT, oleic acid, soy lecithin, Tween 80, PLA polymer, and Pluronic F-68. Characterization involved particle size, PDI, and zeta potential measurements using Dynamic Light Scattering (DLS), and morphology assessments via TEM and SEM. Drug-excipient interactions were analyzed using DSC and FTIR. In vitro release was evaluated using dialysis bags, and in vivo efficacy was tested in scopolamine-induced amnesic mice using the Morris Water Maze (MWM) test. The optimized formulation (NF6) demonstrated suitable particle size, PDI, zeta potential, encapsulation efficiency, and drug loading. NF6 significantly improved memory and exhibited antioxidant activity, indicating its potential for neurodegenerative disorder therapy.

Microbicidal Polymer Nanoparticles Containing Clotrimazole for Treatment of Vulvovaginal Candidiasis

Vulvovaginal candidiasis (VVC) alters the innate cervicovaginal immunity, which provides an important barrier against viruses and other infections. The incidence of this disease has not decreased in the last 30 years, so effective treatments are still needed. Nanoparticles (NPs) of cellulose acetate phthalate (CAP) and clotrimazole (CLZ) were prepared by the emulsification-diffusion method. NPs were characterized using dynamic light scattering, atomic force microscopy and differential scanning calorimetry; their release profile was determined by the dialysis bag technique and mucoadhesion was evaluated with the mucin-particle method. The growth inhibition study of Candida albicans was carried out using the plate counting technique. Finally, accelerated physical stability tests of NPs were carried out, both in water and in SVF. The CAP-CLZ NPs had an average diameter of 273.4 nm, a PDI of 0.284, smooth surfaces and spherical shapes. In vitro release of CLZ from the CAP NPs was categorized with the Weibull model as a matrix system in which initial release was rapid and subsequently sustained. The inhibition of C. albicans growth by the CAP-CLZ NPs was greater than that of free CLZ, and the CAP-only NPs had a microbicidal effect on C. albicans. The NPs showed poor mucoadhesiveness, which could lead to studies of their mucopenetration capacities. An accelerated physical stability test revealed the erosion of CAP in aqueous media. A nanoparticulate system was developed and provided sustained release of CLZ, and it combined an antifungal agent with a microbial polymer that exhibited antifungal activity against C. albicans.Graphical

In vitro drug release profiling of Sirolimus polymeric microparticles coated long-acting stents

In the realm of arterial disease interventions, drug-eluting stents (DES) have become a vital therapeutic choice in preventing atherosclerotic plaque formation and restenosis and facilitating vessel healing. Sirolimus-encapsulated poly Lactic-co-Glycolic acid (PLGA) Microparticles (MPs) were developed using solvent evaporation. MPs were freeze-dried with a cryoprotectant and coated on the stent surface using an efficient and reproducible nitrogen-assisted spray coating technique. The MPs displayed a uniform distribution particle size of 4.38 ± 1.1 μm, span value of 0.88 ± 0.02, coating mass transfer efficiency of 13.45 ± 1.1 % on the stent, and a coating time of ≤ 2 min per stent. Post sterilization, the particle size and morphology of the coated stents remained unchanged. Accelerated in vitro drug release profiles were evaluated under different conditions, indicating significant influences based on dissolution methods ranging from 28.2 %±4.3 %, 42.5 %±5.3 %, 76.6 %±4.7 %, and 84.25 %±3.1 % for dialysis bag (DB), vessel simulating flow-through cell (vFTC), flow-through cell (FTC), and sample and separate (SS) technique respectively for 48 h. The drug release mechanism from the coated stents is governed by the combination of the Korsmeyer Peppas and Higuchi models. The developed dissolution method exhibited discriminative effectiveness when evaluated with critical formulation attributes and process parameter variations. The 48 h accelerated drug release studies correlated well with the 6-month real-time release rate with an R2 value of 0.9142 and Pearson’s R2 of 0.9561. Ex-vivo studies demonstrated the permeation of MPs into artery tissues. Stability studies confirmed that MPs coated stents maintained desired properties at 4 °C and 30 °C/65 % RH for 6 months. Overall, these findings contribute to advancing stent technology, suggesting the potential for improvement of arterial interventions and enhanced patient outcomes.

Development of a 3D Printed Liquid-Core Hydrogel Platform for Real-Time Carbon Nanotube Sensors: A Breakthrough in Minimally Invasive Health Monitoring

The need for minimally invasive, real-time, and low-cost medical sensors holds great potential to revolutionize the healthcare industry. Single-walled carbon nanotube (SWNT)-based near-infrared (nIR) sensors are a relatively new field, able to provide high-quality spatial and temporal information regarding a wide range of cellular signaling molecules, including nitric oxide (NO), and hydrogen peroxide (H2O2). However, their use for in vitro and in vivo applications has been limited due to challenges related to their compatibility with packaging or immobilization techniques. Approaches like surface immobilization on solid substrates and dialysis bag confinement are costly, unstable, and unsuitable for use in settings with limited resources. SWNT sensors have recently been implanted into a large animal model as a proof-of-concept, but the challenge of retaining SWNT is currently restricting the advancement of hydrogel technology in wearable/implantable biosensors. We have developed and optimized a 3D printed liquid-core self-healing hydrogel platform that encapsulates the (AT)15 wrapped-SWNT, a NO sensor, and studied its mechanical and optical characterizations. Notably, after 90-days at 37 °C, the fluorescence intensity exhibited a negligible decrease. Statistical analysis indicates that the change in intensity from day 1 to day 90 was statistically insignificant, highlighting the sensor's robust and stable performance over the extended testing period. A linear calibration curve was obtained when the percent quenching was plotted against the logarithm of NO concentration. Furthermore, a polyvinyl alcohol (PVA) wrapped SWNT, a non-reactive sensor, was implanted into 3D printed liquid-core hydrogel platform and no quenching was observed when it was exposed to NO. Therefore, 3D printed liquid-core hydrogel platforms offer a solution for on-site detection of small-molecule analytes, overcoming a major challenge in real-time medical diagnostics and environmental monitoring.

Mitigating aflatoxin contamination in food product using Limosilactobacillus fermentum LAB212

Various mould fungi responsible for spoilage of ground nut seeds also produce mycotoxins. A strain of Aspergillus flavus VBAH14 isolated from spoiled ground nut seeds was found to produce aflatoxin B1. Thin layer chromatography, high performance liquid chromatography and electronspray ionization-mass spectrometric studies confirm the aflatoxin production. On the other hand, Limosilactobacillus fermentum LAB212, isolated from home made curd was applied against this toxigenic fungus to control its toxin production. Co-culture and dialysis bag assay showed a significant reduction. CFS and cell pellet treatment reduce a significant amount of toxin in culture broth. Moreover LAB212 CFS reduces fungal growth up 99.364%. It was also observed that 80% of aflatoxin was removed by LAB212 cells. Several experiments confirmed that the LAB strain was potent enough to inhibit, reduce, and remove aflatoxin from contaminated solution and ground nuts. Hence suitable formulation of this bacterium and its commercial application can provide us a safe preservation.

Synergistic integration of ternary chalcogenide ZnIn2S4 and brownmillerite Ca2Fe2O5 for efficient degradation of diverse antibiotics: Facilitating easy retrieval with dialysis bag

This work leverages the synergetic effect of chalcogenide ZnIn2S4 (Zinc Indium Sulfide) and brownmillerite Ca2Fe2O5 (Calcium Ferrite) composite (ZC). The ZC composite with surface oxygen vacancy, superior light absorption, charge separation, good stability, and recyclability was prepared. The material could effectively degrade various antibiotics (having different structures), such as Metronidazole, Nitrofurantoin, Sulfamethoxazole, and Tetracycline with 98 %, 99.5 %, 98.4 %, and 82.4 % efficiency respectively. A customized LED chamber was used as a cost-efficient photoreactor. Post-degradation, dialysis bags were used effectively to retrieve the photocatalytic material from water, as corroborated by leaching studies based on the Inductively coupled plasma-optical emission spectrometry (ICP-OES). This work marks a significant leap forward in the quest for wastewater treatment, offering a versatile solution.